The United States Patent and Trademark Office (USPTO) has issued patent US12582724B2, granting Duke University exclusive rights to "Compositions comprising microbial polypeptides for degrading glycogen and methods for the treatment of glycogen storage diseases." The patent claims cover specific nucleic acid sequences encoding microbial polypeptides optimized for expression in mammalian cells, along with associated vectors and therapeutic methods for treating glycogen storage diseases and other inherited conditions.

This patent grant is primarily relevant to entities involved in pharmaceutical research and development, particularly those focusing on genetic therapies and rare diseases. While it does not impose direct compliance obligations on other regulated entities, it signifies intellectual property protection in the biotechnology sector. Companies operating in this space should be aware of this patent's scope to avoid potential infringement issues.